Clinical characterization of imuthiol.
Imuthiol is a nontoxic agent recruting and regulating T cells. Phase III studies in chronic bronchitis and bronchiectasis showed that immune functions were restored to normal, or near normal values. Cure was obtained in rheumatoid arthritis, tuberculosis and chronic infections in the elderly. Imuthiol is an effective agent for the treatment of syndromes and disease states where the underlying defect is a T-cell deficiency or dysfunction.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001424:Bacterial Infections / Q000188:drug therapy; D001987:Bronchiectasis / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004050:Ditiocarb / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D013601:T-Lymphocytes / Q000187:drug effects; D013859:Thiocarbamates / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D000276:Adjuvants, Immunologic; D013859:Thiocarbamates; D004050:Ditiocarb